Key facts
- This page summarizes Dean J. Mitchell's Form 4 filing for ImmunoGen, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jul 2022, 16:49.
Dean J. Mitchell - 30 Jun 2022 Form 4 Insider Report for ImmunoGen, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 30 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jul 2022, 16:49:28 UTC
- Prior SEC filing
- 17 Jun 2022
- Next SEC filing
- 04 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Renee Lentini, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dean J. Mitchell filed Form 4 for ImmunoGen, Inc. on 05 Jul 2022.
Change
- Previous filing in this sequence was filed on 17 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMGN
transaction
Derivative
Deferred Share Unit
Award
- Transaction value
- $0
- Shares
- +3,333
- Change %
- +2.5%
- Price
- $0.000000
- Shares after
- 136,505
- Date
- 30 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,333
- Exercise price
- $0.000000
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
Footnote F2
The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
Footnote F3
The deferred share units vest upon issuance.